Relapsed B Acute Lymphoblastic LeukaemiaPhase 2/3NCT03937544
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
A Phase 2/3 study testing CD19 CAR-T CELLS, Cyclophosphamide and Fludarabine in people with Relapsed B Acute Lymphoblastic Leukaemia and Refractory B Acute Lymphoblastic Leukaemia, run by National University of Malaysia at 1 site in Malaysia.
Trial summary
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia Read more about this study
- Who is it for?
- Ages 13 to 65 years
- Conditions the study is for
- Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia
- What is being tested?
- CD19 CAR-T CELLS, Cyclophosphamide and Fludarabine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteMalaysia
- Study dates
- 19 Mar 2019to 18 Mar 2027
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients with relapsed/refractory B-ALL in accordance with World Health Organization (WHO) classification by virtue of BM morphology, flow cytometry, cytogenetics and molecular genetics
- Age between ≥13 to ≤ 65 years
- No detectable leukaemia in the CSF (CNS-1)
- CNS leukaemia without clinically evident neurological symptoms (CNS-2; with <5 WBC per μL and cytology positive for blasts)
- Adequate organ function as defined by a creatinine clearance > 50 ml/min, serum total bilirubin < 5 times the normal value, left ventricular ejection fraction > 40%
- ECOG performance status ≤ 2
Show all 10Show fewer
- Life expectancy > 3 months
- Post allogeneic HSCT must be ≥ Day +100 with no evidence of active GVHD and not receiving immunosuppression
- Female patients of child bearing age must have negative pregnancy test and is on highly effective contraception methods
- Male patients must use highly effective contraception methods
Who cannot join
- Patients with CNS-3 leukaemia.
- Active cancer (other than B-ALL).
- Evidence of severe lung, heart (NYHA class III/IV, arrhythmia, AV block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder.
- Presence of active autoimmune disease or atopic allergy.
- HIV serology positivity.
- Active Hepatitis B or C infection as evidenced by quantitative viral PCR assay.
Show all 10Show fewer
- Uncontrolled sepsis
- Pregnant / nursing female.
- Ongoing prednisolone > 1mg/kg daily or equivalent.
- Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Malaysia1 site, 1 recruiting
- Recruiting
UKM Medical Centre
Bandar Tun Razak, Kuala Lumpur, 56000
S Fadilah Abdul Wahid, MD, DrIntMed, PhD, +60391456450, sfadilah@ppukm.ukm.edu.my
Wan Fariza Wan Jamaludin, MD,DrIntMed, +60391457709, wanfariza@ppukm.ukm.edu.my
About this study
Official title: A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
- Being tested
- CD19 CAR-T CELLS, Cyclophosphamide, Fludarabine
- Medical subject headings
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CD19 CAR-T CELLSBiological
CD19 CAR-T cells will be administered after completion of the lymphodepletion chemotherapy.
CyclophosphamideDrug
Patients will receive lymphodepleting chemotherapy consisting of Cyclophosphamide 250 - 300 mg/m2/day IV(Day -5, Day -4, Day -3 ).
FludarabineDrug
Patients will receive lymphodepleting chemotherapy consisting of Fludarabine 25-30 mg/m2/day IV (Day -5, Day -4, Day -3 ).
| Study group | Role | What they receive |
|---|---|---|
| CD19 CAR-T CELLS | Experimental | A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously. Receives: Biological: CD19 CAR-T CELLS; Drug: Cyclophosphamide; Drug: Fludarabine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall response rate (ORR)
Overall Response Rate (ORR) defined as Complete Response (CR) and CR with incomplete blood recovery (CRi) according to WHO criteria.
Measured: Participants will be followed for the duration of the treatment, with an expected average of 3 months.
Complete response (CR)
Duration of response defined from the time when criteria for response (CR or CRi) are met to the first documentation of relapse or progression.
Measured: 12 Months
CR with incomplete blood recovery (CRi).
Duration of response defined from the time when criteria for response (CR or CRi) are met to the first documentation of relapse or progression.
Measured: 12 Months
Secondary outcomes (4)
Overall survival (OS)
Overall Survival (OS) defined as the time from treatment to the date of death due to any cause.
Measured: 12 Months, 24 Months
Progression free survival (PFS)
Progression Free Survival (PFS) defined as the time from treatment to first documentation of objective leukemic progression (date of leukaemia assessment documenting progressive disease) or to death due to any cause. Progression is assessed by BM biopsy or CSF analysis according to NCCN criteria. It is assessed at Day 30 and monthly thereafter, or earlier if clinically indicated.
Measured: 12 Months, 24 Months
Time to next treatment (TTNT)
Time To Next Treatment (TTNT) defined as the end of study treatment until the institution of the next therapy.
Measured: 12 Months, 24 Months
Percentage of adverse events
Percentage of participants with adverse events
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2019
- Study start19 Mar 2019
- Primary completion18 Jan 2027 (estimated)
- Study completion18 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Relapsed B Acute Lymphoblastic LeukaemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University of Malaysia
- Sponsor type
- University, hospital or other
- Collaborators
- Gaia Science
- Responsible party
- Principal investigator, Prof. Dr S Fadilah Abdul Wahid, National University of Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03937544
- Sponsor's protocol ID
- JEP-2019-003
- Other IDs
- FF-2019-138
- Status last verified
- May 2025
- First submitted
- 22 Apr 2019
- Last updated
- 29 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia
- ClinicalTrials.gov ID
- NCT03937544
- Acronym / sponsor ID
- JEP-2019-003
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- National University of MalaysiaUniversity, hospital or other
- Collaborators
- Gaia Science
- Study start
- 19 Mar 2019 (actual)
- Primary completion
- 18 Jan 2027 (estimated)
- Study completion
- 18 Mar 2027 (estimated)
- First posted
- 3 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CD19 CAR-T CELLS | Experimental | Biological: CD19 CAR-T CELLS, Drug: Cyclophosphamide, Drug: FludarabineA conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously. |
Who may qualify
- Ages
- 13 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (10 listed)
- Patients with relapsed/refractory B-ALL in accordance with World Health Organization (WHO) classification by virtue of BM morphology, flow cytometry, cytogenetics and molecular genetics
- Age between ≥13 to ≤ 65 years
- No detectable leukaemia in the CSF (CNS-1)
- CNS leukaemia without clinically evident neurological symptoms (CNS-2; with <5 WBC per μL and cytology positive for blasts)
- Adequate organ function as defined by a creatinine clearance > 50 ml/min, serum total bilirubin < 5 times the normal value, left ventricular ejection fraction > 40%
Key exclusion criteria (10 listed)
- Patients with CNS-3 leukaemia.
- Active cancer (other than B-ALL).
- Evidence of severe lung, heart (NYHA class III/IV, arrhythmia, AV block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder.
- Presence of active autoimmune disease or atopic allergy.
- HIV serology positivity.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CD19 CAR-T CELLSCD19 CAR-T cells will be administered after completion of the lymphodepletion chemotherapy. | Biological | CD19 CAR-T CELLS |
| CyclophosphamidePatients will receive lymphodepleting chemotherapy consisting of Cyclophosphamide 250 - 300 mg/m2/day IV(Day -5, Day -4, Day -3 ). | Drug | CD19 CAR-T CELLS |
| FludarabinePatients will receive lymphodepleting chemotherapy consisting of Fludarabine 25-30 mg/m2/day IV (Day -5, Day -4, Day -3 ). | Drug | CD19 CAR-T CELLS |
Primary outcome
Overall response rate (ORR)
Time frame: Participants will be followed for the duration of the treatment, with an expected average of 3 months.
Overall Response Rate (ORR) defined as Complete Response (CR) and CR with incomplete blood recovery (CRi) according to WHO criteria.
Complete response (CR)
Time frame: 12 Months
Duration of response defined from the time when criteria for response (CR or CRi) are met to the first documentation of relapse or progression.
CR with incomplete blood recovery (CRi).
Time frame: 12 Months
Duration of response defined from the time when criteria for response (CR or CRi) are met to the first documentation of relapse or progression.
4 secondary outcomes
Overall survival (OS)
Time frame: 12 Months, 24 Months
Progression free survival (PFS)
Time frame: 12 Months, 24 Months
Time to next treatment (TTNT)
Time frame: 12 Months, 24 Months
Percentage of adverse events
Time frame: 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Relapsed B Acute Lymphoblastic Leukaemia
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
RecruitingPhase 1
A Phase I Dose Finding Study of MB-CART2219.1
Lymphoma, CLL
Not yet recruitingPhase 1
BLinatumomab and iNKT in Relapsed B-Cell ALL
B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia)
RecruitingPhase 1
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
Not yet recruitingPhase 2
Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia
Acute Lymphobkastic Leukemia, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing CD19 CAR-T CELLS, Cyclophosphamide and Fludarabine in people with Relapsed B Acute Lymphoblastic Leukaemia and Refractory B Acute Lymphoblastic Leukaemia, run by National University of Malaysia at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact S Fadilah Abdul Wahid, MD, DrIntMed, PhD (+60391456450, sfadilah@ppukm.ukm.edu.my), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall response rate (ORR) (time frame: Participants will be followed for the duration of the treatment, with an expected average of 3 months.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2025.